Aisling Capital’s Aimmune Therapeutics AIMT Stock Holding History

Aisling Capital’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$26M	Sell	1,240,000 -750,000	-38%	-$15.3M	57.34%	1
2019 Q2	$41.4M	Hold	1,990,000	–	–	68.67%	1
2019 Q1	$44.5M	Hold	1,990,000	–	–	66.84%	1
2018 Q4	$47.6M	Hold	1,990,000	–	–	13.48%	2
2018 Q3	$54.3M	Sell	1,990,000 -250,000	-11%	-$7.07M	11.73%	2
2018 Q2	$60.2M	Hold	2,240,000	–	–	7.91%	2
2018 Q1	$71.3M	Hold	2,240,000	–	–	12.71%	2
2017 Q4	$84.7M	Sell	2,240,000 -750,000	-25%	-$24.2M	16.74%	2
2017 Q3	$74.1M	Hold	2,990,000	–	–	12.18%	2
2017 Q2	$61.5M	Hold	2,990,000	–	–	10.53%	2
2017 Q1	$65M	Hold	2,990,000	–	–	11.83%	3
2016 Q4	$61.1M	Hold	2,990,000	–	–	14.22%	3
2016 Q3	$44.9M	Hold	2,990,000	–	–	9.24%	4
2016 Q2	$32.4M	Hold	2,990,000	–	–	7.64%	3
2016 Q1	$40.5M	Hold	2,990,000	–	–	8.12%	3
2015 Q4	$55.2M	Buy	2,990,000 +170,000	+6%	+$3.14M	9.51%	4
2015 Q3	$71.4M	Buy	+2,820,000	New	+$65.9M	12.55%	2

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aisling Capital's AIMT Position: Q3 2019 in Review

Aisling Capital reduced its Aimmune Therapeutics (AIMT) stake by 38% in Q3 2019, selling an estimated $15.3M and leaving 1,240,000 shares worth $26M. The position accounts for 57.34% of the portfolio, ranked #1.

Aisling Capital first reported a position in AIMT in Q3 2015 and has held it in 17 quarters since. The position peaked at $84.7M in Q4 2017. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

Aisling Capital held 1,240,000 shares of Aimmune Therapeutics worth $26M as of Q3 2019.
Aisling Capital sold 750,000 Aimmune Therapeutics shares in Q3 2019, an estimated $15.3M.
Aimmune Therapeutics made up 57.34% of Aisling Capital's portfolio in Q3 2019, its #1 holding.
Aisling Capital first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 17 quarters since.
Aisling Capital's Aimmune Therapeutics position peaked at $84.7M in Q4 2017.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Aisling Capital's 13F filing for Q3 2019, filed 13 Nov 2019.